Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1011

—

40031bd9-b0c4-5e85-ae5b-7771e80fb78f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.621
  • G2M_CHECKPOINT+0.556
  • MYC_TARGETS_V1+0.519
  • MYC_TARGETS_V2+0.501
  • MTORC1_SIGNALING+0.470
  • CHOLESTEROL_HOMEOSTASIS+0.435
  • UNFOLDED_PROTEIN_RESPONSE+0.405
  • PROTEIN_SECRETION+0.396
  • MITOTIC_SPINDLE+0.388
  • OXIDATIVE_PHOSPHORYLATION+0.359

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.583
  • INTERFERON_GAMMA_RESPONSE-0.553
  • ALLOGRAFT_REJECTION-0.450
  • IL6_JAK_STAT3_SIGNALING-0.343
  • APICAL_SURFACE-0.316
  • KRAS_SIGNALING_DN-0.314
  • COAGULATION-0.297
  • HEDGEHOG_SIGNALING-0.288
  • KRAS_SIGNALING_UP-0.280
  • COMPLEMENT-0.268

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-BT-A20N-01A-11R-A14Y-07
bladder-landscape@3
——0.949
2MNG1063
mng-umap@100
——0.941
3TCGA-21-1075-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.921
41764b9ab-4f37-47c5-8225-40c574433f40
colon-landscapes@1
——0.915
5MDT-AP-2956
medullo-epn-umap@date-based
MedMedulloblastoma0.914
6BS_G23JJAZY
brain-umap@2
Supratentorial Ependymoma—0.910
7BS_G23JJAZY
medullo-epn-umap@date-based
EPNSupratentorial EPN0.907
8TCGA-46-3768-01A-01R-0980-07
lung-landscapes@6
—cohortSQ20.899
9TCGA-DQ-7588-01A-11R-2081-07
head-neck@1
——0.894
10SRR4296106
lung-landscapes@6
—cohortSQ10.894

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.621Inavolisib— uncovered
G2M_CHECKPOINT0.556Inavolisib— uncovered
MYC_TARGETS_V10.519Inavolisib— uncovered
MYC_TARGETS_V20.501Idelalisib— uncovered
MTORC1_SIGNALING0.470Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.435Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.405Idelalisib— uncovered
PROTEIN_SECRETION0.396Remibrutinib— uncovered
MITOTIC_SPINDLE0.388Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.359Remibrutinib— uncovered
GLYCOLYSIS0.318Inavolisib— uncovered
DNA_REPAIR0.300Idelalisib— uncovered
FATTY_ACID_METABOLISM0.279Inavolisib— uncovered
ADIPOGENESIS0.198Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.190Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.161Inavolisib— uncovered
ANDROGEN_RESPONSE0.138Inavolisib— uncovered
PEROXISOME0.092Idelalisib— uncovered
UV_RESPONSE_DN0.069Inavolisib— uncovered
BILE_ACID_METABOLISM0.055Inavolisib— uncovered